title: Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
abstract: The World Health Organization (WHO) classification system has recently strengthened the diagnostic criteria for essential thrombocythemia (ET) by lowering the threshold platelet count, underscoring its morphological distinction from early/prefibrotic myelofibrosis (MF) and incorporating molecular markers of clonality. The International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) examined the clinical relevance of this process in 1104 cases of locally diagnosed 'ET' and showed worse overall, leukemia-free and fibrosis-free survival, and a higher risk of bleeding in early/prefibrotic MF (n=180) vs WHO-defined ET (n=891). The risk of thrombosis was similar between the two entities and, in WHO-defined ET, was predicted by thrombosis history, older age, cardiovascular risk factors and JAK2V617F. A prognostic model based on these risk factors identified patient groups in ET with residual risk of thrombosis, despite treatment with conventional therapy. The main objectives of the current perspective are to underscore the prognostic importance of morphological confirmation in the diagnosis of ET and provide management recommendations, in both WHO-defined ET and early/prefibrotic MF, based on observations from the aforementioned IWG-MRT and other studies. In so doing, we are fully cognizant and sympathetic of the fact that some of our recommendations need to be tested in prospective controlled studies.
authors.affiliation: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. tefferi.ayalew@mayo.edu
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: T
authors.initials: T
authors.lastname: Barbui
mesh_terms: D003937:Diagnosis, Differential; D006801:Humans; D011087:Polycythemia Vera / Q000175:diagnosis; D055728:Primary Myelofibrosis / Q000175:diagnosis; D011379:Prognosis; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*
references.citation: Am J Hematol. 2012 Feb;87(2):203-4
references.pmid: 22237692
references.citation: Exp Hematol. 2009 Oct;37(10):1186-1193.e7
references.pmid: 19616600
references.citation: Am J Hematol. 2010 Jan;85(1):62-9
references.pmid: 19844986
references.citation: Blood. 2012 Dec 20;120(26):5128-33; quiz 5252
references.pmid: 23033268
references.citation: Ann Hematol. 2004 Aug;83(8):504-12
references.pmid: 15164229
references.citation: Blood. 2011 Jun 2;117(22):5857-9
references.pmid: 21490340
references.citation: Leukemia. 2012 Jul;26(7):1452-7
references.pmid: 22252311
references.citation: Thromb Res. 2012 Mar;129(3):341-4
references.pmid: 22142668
references.citation: Leukemia. 2010 Jun;24(6):1128-38
references.pmid: 20428194
references.citation: J Thromb Haemost. 2011 Jan;9(1):185-91
references.pmid: 20955349
references.citation: Blood. 2012 Apr 12;119(15):3595-603
references.pmid: 22234683
references.citation: Am J Hematol. 2012 Jul;87(7):669-72
references.pmid: 22573503
references.citation: Leukemia. 2008 Jan;22(1):14-22
references.pmid: 17882280
references.citation: Leukemia. 2013 Oct;27(10):1953-8
references.pmid: 23467025
references.citation: J Clin Oncol. 2011 Aug 10;29(23):3179-84
references.pmid: 21747083
references.citation: Blood. 2012 Aug 9;120(6):1197-201
references.pmid: 22740446
references.citation: Blood. 2010 Aug 26;116(8):1205-10; quiz 1387
references.pmid: 20508163
references.citation: Arch Intern Med. 2007 Aug 13-27;167(15):1593-9
references.pmid: 17698681
references.citation: Leukemia. 2012 Apr;26(4):716-9
references.pmid: 21926959
references.citation: Am J Hematol. 2012 Mar;87(3):285-93
references.pmid: 22331582
references.citation: N Engl J Med. 2013 Jan 3;368(1):22-33
references.pmid: 23216616
references.citation: Blood. 2010 Feb 4;115(5):1054-61
references.pmid: 19887674
references.citation: Blood. 2006 Sep 1;108(5):1781-2
references.pmid: 16926301
references.citation: Blood. 2012 Apr 12;119(15):3377-8
references.pmid: 22500051